Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong Q4 FY26 results with revenue of ₹2,034 million (up 22% YoY) and PAT of ₹453 million (up 69% YoY). For the full year FY26, revenue grew 17% to ₹7,458 million and PAT jumped 30% to ₹1,736 million. EBITDA margin held steady at 31% and PAT margin at 23% in FY26. Human Nutrition remains the dominant segment contributing 63% of quarterly revenue. Geographically, India and Asia (ex-India) showed strong growth of 51% and 53% respectively in Q4. The company operates across four segments: Human Nutrition, Animal Nutrition, Industrial Bio-Processing, and Specialized Manufacturing, and positions itself as the 2nd largest integrated enzyme player globally. Management outlined focus areas including bio-catalysis for API manufacturers, probiotic expansion, and baking solutions, but no specific margin guidance or multi-year quantitative targets were provided in this filing.
The company delivered robust double-digit growth across all key metrics with margin expansion, signaling operational efficiency. The strong PAT growth of 69% YoY in Q4 is particularly positive for shareholders. However, this is a historical results presentation with no forward guidance or new catalysts disclosed.